The Full List of 50 Biotechnology Unicorn Startups (2026)
The biotechnology industry is home to 50 unicorn startups pursuing a wide range of scientific goals. These companies are developing new technologies for everything from tissue regeneration to de-extinction.
The sector includes major players like Biosplice Therapeutics, valued at $12 billion. It also features companies like Neuralink, which has raised $1.3 billion to build brain-computer interfaces.
Below is the full list of 50 Biotechnology unicorn startups at this time.
Top 10 Most Valuable Biotechnology Unicorns
Biosplice Therapeutics develops first-in-class, small-molecule drugs based on the science of alternative splicing. Their clinical pipeline focuses on treating major diseases, including a lead candidate for osteoarthritis and other programs in oncology.
| Valuation | $12B |
| Headquarters | San Diego, California, United States |
| Year Founded | 2008 |
| Founders | Osman Kibar |
| Funding Amount | $778M |
| Company Size | Mid-Size Team (51-250) |
| Last Funding Status | Venture Round |
| Top Investors | Vickers Venture Partners, aMoon Fund, Verition Fund Management, Sands Capital Ventures, Swicorp |
Neuralink develops implantable brain-computer interfaces designed to connect the human brain directly to computers. The technology's first application aims to give people with paralysis the ability to control digital devices with their thoughts alone.
| Valuation | $10B (Joined July 2021) |
| Headquarters | Fremont, California, United States |
| Year Founded | 2016 |
| Founders | Dongjin Seo, Elon Musk, Max Hodak |
| Funding Amount | $1.3B |
| Company Size | Large Team (251-1,000) |
| Last Funding Status | Venture Round |
| Top Investors | Founders Fund, Sequoia Capital, Craft Ventures, Valor Equity Partners, Lightspeed Venture Partners |
Colossal Biosciences pioneers de-extinction using advanced biotechnology and genetic engineering. Their primary mission involves using gene editing technologies to resurrect extinct species, most notably the Woolly Mammoth.
| Valuation | $10B |
| Headquarters | Austin, Texas, United States |
| Year Founded | 2021 |
| Founders | Andrew Busey, Ben Lamm, Brian Beard, George Church, Kent Wakeford, Peter Phillips |
| Funding Amount | $568.1M |
| Company Size | Mid-Size Team (51-250) |
| Last Funding Status | Series C |
| Top Investors | Liquid 2 Ventures, Builders VC, Capital Factory, Draper Associates, US Innovative Technology Fund |
Benchling builds the R&D Cloud, a unified software platform designed for scientists and biotechnology organizations. Their system helps centralize complex scientific data, allowing research teams to collaborate more effectively and bring new products to market faster.
| Valuation | $6.1B (Joined April 2021) |
| Headquarters | San Francisco, California, United States |
| Year Founded | 2012 |
| Founders | Ashutosh Singhal, Cory Li, Sam Wickramasekara |
| Funding Amount | $411.9M |
| Company Size | Large Team (251-1,000) |
| Last Funding Status | Series F |
| Top Investors | Andreessen Horowitz, Franklin Templeton, Benchmark, Lux Capital, Menlo Ventures |
Biocon Biologics develops and manufactures high-quality, affordable biosimilars for patients across the globe. The company focuses on complex therapies in areas like diabetes, oncology, and immunology to expand access to critical treatments.
| Valuation | $6B |
| Headquarters | Bangalore, Karnataka, India |
| Year Founded | 1978 |
| Founders | Kiran Mazumdar-Shaw |
| Funding Amount | $482.4M |
| Company Size | Enterprise Organization (5,001+) |
| Last Funding Status | Corporate Round |
| Top Investors | Serum Life Sciences, Tata Capital, Goldman Sachs, True North, ADQ |
Color provides the healthcare infrastructure for employers, health plans, and governments to deliver care programs to their populations. Their platform focuses on making services like cancer screening and prevention more accessible through at-home diagnostics and virtual-first care.
| Valuation | $5B (Joined January 2021) |
| Headquarters | Burlingame, California, United States |
| Year Founded | 2013 |
| Founders | Elad Gil, Nish Bhat, Othman Laraki, Taylor Sittler |
| Funding Amount | $482M |
| Company Size | Large Team (251-1,000) |
| Last Funding Status | Series E |
| Top Investors | CRV, Caffeinated Capital, SV Angel, General Catalyst, Khosla Ventures |
Sinovac Life Sciences researches, develops, and manufactures human vaccines. As a research-based company, they manage the entire product lifecycle from initial studies through to commercial sales.
| Valuation | $3B |
| Headquarters | Beijing, Beijing, China |
| Year Founded | 2009 |
| Founders | Weidong Yin |
| Funding Amount | $500M |
| Company Size | No Data |
| Last Funding Status | Corporate Round |
| Top Investors | Sino Biopharmaceutical |
Freenome develops blood tests for early cancer detection using a comprehensive multiomics platform. These tests are designed to make routine screening more accessible through a simple blood draw.
| Valuation | $2.62B (Joined August 2020) |
| Headquarters | South San Francisco, California, United States |
| Year Founded | 2014 |
| Founders | Charles Roberts, Gabriel Otte, Michael Otte, Riley Ennis |
| Funding Amount | $1.5B |
| Company Size | Large Team (251-1,000) |
| Last Funding Status | Corporate Round |
| Top Investors | Polaris Partners, Founders Fund, Verily, Andreessen Horowitz, RA Capital Management |
Insitro applies machine learning and high-throughput biology to rethink the drug discovery and development process. Their platform generates massive datasets to build predictive models of disease, aiming to uncover new therapeutic solutions.
| Valuation | $2.44B (Joined March 2021) |
| Headquarters | South San Francisco, California, United States |
| Year Founded | 2018 |
| Founders | Daphne Koller |
| Funding Amount | $643M |
| Company Size | Large Team (251-1,000) |
| Last Funding Status | Series C |
| Top Investors | Verily, Temasek Holdings, ARCH Venture Partners, BlackRock, Andreessen Horowitz |
Inari develops seeds for a more sustainable food system using its proprietary SEEDesign™ platform. The resulting seeds are engineered to significantly increase yields while reducing the need for water and fertilizer.
| Valuation | $2.17B (Joined May 2021) |
| Headquarters | Cambridge, Massachusetts, United States |
| Year Founded | 2016 |
| Founders | David Berry, Ignacio Martinez, John Casey |
| Funding Amount | $753M |
| Company Size | Large Team (251-1,000) |
| Last Funding Status | Series G |
| Top Investors | Pavilion Capital, G Squared, Abu Dhabi Investment Authority, Acre Venture Partners, Flagship Pioneering |
The Remaining 40 Biotechnology Unicorns
The top 10 companies only scratch the surface of what's happening in biotechnology. Founders around the world are tackling big problems in health and science.
Many of these startups are in the United States, but companies in China, Japan, and India are also growing quickly. Here’s a look at the other unicorns shaping the future of biotech.
| Unicorn Startup | Country | Year Founded | Amount Raised | Valuation |
|---|---|---|---|---|
 Xaira Therapeutics | United States | 2023 | $1B | $2.15B |
 Pivot Bio | United States | 2011 | $616.9M | $2B |
 ConcertAI | United States | 2018 | $300M | $2B |
 Tessera Therapeutics | United States | 2018 | $623.1M | $2B |
 Orna Therapeutics | United States | 2019 | $321M | $2B |
 Kriya Therapeutics | United States | 2019 | $921.3M | $2B |
 Opentrons | United States | 2014 | $240M | $2B |
 Pathos | United States | 2020 | $447M | $2B |
 Preferred Networks | Japan | 2014 | ¥44.6B | $2B |
 Perfect Day | United States | 2014 | $801.5M | $2B |
 Molbio Diagnostics | India | 2000 | $117.5M | $2B |
 Solugen | United States | 2016 | $855.8M | $2B |
 SFCC | China | 2016 | CN¥5.6B | $2B |
 Apeel Sciences | United States | 2012 | $719.1M | $2B |
 NantOmics | United States | 2012 | $250.8M | $2B |
 Generate Biomedicines | United States | 2018 | $693M | $1.36B |
 Spiber | Japan | 2007 | $976.1M | $1.22B |
 BillionToOne | United States | 2016 | $425.9M | $1B |
 Insilico Medicine | United States | 2014 | $624.3M | $1B |
 Ultima Genomics | United States | 2016 | $600M | $1B |
 Element Biosciences | United States | 2017 | $678M | $1B |
 Resilience | United States | 2020 | $3.4B | $1B |
 Enveda Biosciences | United States | 2019 | $529.9M | $1B |
 Immunai | United States | 2018 | $295M | $1B |
 Human Longevity | United States | 2013 | $369.8M | $1B |
 VectorBuilder | United States | 2015 | CN¥410M | $1B |
 Owkin | United States | 2016 | $304.1M | $1B |
 Aragen Life Sciences | India | 2001 | $184.2M | $1B |
 IntraBio | United States | 2015 | $50.6M | $1B |
 Wilson Wolf Corporation | United States | 1998 | $257M | $1B |
 Mammoth Biosciences | United States | 2017 | $359.5M | $1B |
 MegaRobo | China | 2016 | $425.8M | $1B |
 Eat Just | United States | 2011 | $465M | $1B |
 Formation Bio | United States | 2013 | $528M | $1B |
 LetsGetChecked | United States | 2015 | $708M | $1B |
 Bluepha | China | 2016 | CN¥2B | $1B |
 Belief BioMed | China | 2018 | $204M | $1B |
 Haihe Biopharma | China | 2011 | $317.6M | $1B |
 iCarbonX | China | 2015 | $200M | $1B |
 Letu | China | 2016 | CN¥200M | $1B |
